Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) EBITDA Margin (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed EBITDA Margin for 16 consecutive years, with 161.38% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 19616.0% to 161.38% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 4.97% through Dec 2025, down 2153.0% year-over-year, with the annual reading at 4.97% for FY2025, 2153.0% down from the prior year.
  • EBITDA Margin hit 161.38% in Q4 2025 for Ironwood Pharmaceuticals, down from 61.84% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 376.14% in Q2 2021 to a low of 1014.58% in Q2 2023.
  • Historically, EBITDA Margin has averaged 11.83% across 5 years, with a median of 36.73% in 2021.
  • Biggest five-year swings in EBITDA Margin: plummeted -105272bps in 2023 and later soared 104104bps in 2024.
  • Year by year, EBITDA Margin stood at 35.32% in 2021, then rose by 29bps to 45.59% in 2022, then dropped by -30bps to 31.98% in 2023, then rose by 9bps to 34.78% in 2024, then crashed by -564bps to 161.38% in 2025.
  • Business Quant data shows EBITDA Margin for IRWD at 161.38% in Q4 2025, 61.84% in Q3 2025, and 53.17% in Q2 2025.